BB Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
For the six months, revenue was CHF 0.522 million compared to CHF 0.783 million a year ago. Net loss was CHF 267.33 million compared to CHF 532.93 million a year ago. Basic loss per share from continuing operations was CHF 4.87 compared to CHF 9.66 a year ago. Diluted loss per share from continuing operations was CHF 4.87 compared to CHF 9.66 a year ago.